Skip to Content

Bio-Path Holdings Inc BPTH

Morningstar Rating
$2.14 +0.14 (7.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BPTH is trading at a 135% premium.
Price
$1.99
Fair Value
$4.28
Uncertainty
Extreme
1-Star Price
$68.88
5-Star Price
$8.26
Economic Moat
Rbhw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BPTH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.00
Day Range
$2.012.21
52-Week Range
$2.0044.60
Bid/Ask
$2.04 / $2.15
Market Cap
$3.54 Mil
Volume/Avg
91,160 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
10

Valuation

Metric
BPTH
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BPTH
Quick Ratio
0.55
Current Ratio
1.60
Interest Coverage
Quick Ratio
BPTH

Profitability

Metric
BPTH
Return on Assets (Normalized)
−239.99%
Return on Equity (Normalized)
−457.66%
Return on Invested Capital (Normalized)
−437.08%
Return on Assets
BPTH
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMdvlyshrrPtksk$586.3 Bil
VRTX
Vertex Pharmaceuticals IncYtyfmxxvQqxmyjs$114.1 Bil
REGN
Regeneron Pharmaceuticals IncWgbfsjlpmWrszjq$109.5 Bil
MRNA
Moderna IncWxqvkdcYyb$54.0 Bil
BNTX
BioNTech SE ADRGvydmrfhHzzpb$22.2 Bil
ARGX
argenx SE ADRKgvffxrjrPnld$21.3 Bil
ALNY
Alnylam Pharmaceuticals IncCncxbgzyWcsmnnn$18.9 Bil
BMRN
Biomarin Pharmaceutical IncPqhbmtnYgprzk$14.7 Bil
INCY
Incyte CorpNcskfcfzJgcvcsf$12.9 Bil
RPRX
Royalty Pharma PLC Class ASchjpsclMtflqp$12.3 Bil

Sponsor Center